Larsen, RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of 211AT-labeled chimeric monoclonal antibodies on human glioma and melanoma cells in vitro. Radiation Res. 1998; 149:155-162
Larsen RH, Vaidyanathan G, Zalutsky MR. The cytotoxicity of a-particle emitting 5-[211At]astato2'-deoxyuridine in human cancer cells. Int J Radiation Biol. 1997; 72:79-90
Reist CJ, Archer GE, Wikstrand CJ, Bigner DD, Zalutsky MR. Improved targeting of an anti-EGFRvIII monoclonal antibody in tumor xenografts after labeling using N-succinimdyl 5-iodo-3-pyridinecarboxylate. Cancer Res., 1997; 57:1510-1515
4. Vaidyanathan, G., Larsen, R.H., and Zalutsky, M.R.:5-[211At]astato-2\'-deoxyuridine, an à-particle emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 1996; 56:1204-1209.
5. Reist, C.J., Garg, P.K., Alston, K.L., Bigner, D.D., and Zalutsky, M.R.: Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridine-carboxylate: in vitro studies. Cancer Res., 1996;56:4970-4977.
Olafsen T, Brugland S, Zalutsky MR, Sandlie I. Cloning and sequencing of V genes from anti-osteosarcoma monoclonal antibodies TP-1 and TP-3: Location of lysine residues and implications for radiolabeling. Nucl Med Biol 1995; 22:765-772
2. Zalutsky, M.R., McLendon, R., Garg, P.K., Archer, G.E., Schuster, J.M., and Bigner, D.D.: Radioimmunotherapy of neoplastic meningitis in rats using an à-particle-emitting immunoconjugate. Cancer Res. 1994;54:4719-4725.
3. Page, R.L., Garg, P.K., Garg, S., Archer, G.E., Bruland, .S., and Zalutsky, M.R.: Positron emission tomographic imaging of osteosarcoma in dogs using an 18F-labeled monoclonal antibody Fab fragment. J. Nucl. Med. 1994; 35:1506-1513.
1. Zalutsky, M.R., Garg, P.K., Friedman, H.S., and Bigner, D.D.: Labeling monoclonal antibodies and F(ab')2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl. Acad. Sci. USA 1989;86:7149-7153.
